Published in J Immunol on February 01, 1993
CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol (2004) 2.71
Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity. J Cell Biol (1995) 0.90
CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells. Immunology (1995) 0.81
The homing receptor CD44 is involved in the progression of precancerous gastric lesions in patients infected with Helicobacter pylori and in development of mucous metaplasia in mice. Cancer Lett (2015) 0.75
Evaluation of posttransplant methotrexate to facilitate engraftment in the canine major histocompatibility complex-haploidentical nonmyeloablative transplant model. Transplantation (2010) 0.75
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol (2017) 0.75
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia (2006) 1.51
Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant (2006) 1.29
Characterization of monoclonal antibodies that recognize canine CD34. Blood (1998) 1.13
Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res (2000) 1.09
Allogeneic transplant of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood (1996) 1.03
Theratope vaccine (STn-KLH). Expert Opin Biol Ther (2001) 1.03
Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol (2005) 1.02
Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood (1998) 1.00
Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine (2001) 0.99
differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1. J Biol Chem (2001) 0.95
Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells. Keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-gamma-treated keratinocytes. J Immunol (1991) 0.95
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant (2011) 0.93
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant (2000) 0.93
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant (2005) 0.93
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant (2010) 0.91
DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood (1995) 0.91
Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant (2008) 0.89
Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys J (1998) 0.88
Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology (1999) 0.88
Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP. Blood (1992) 0.87
What radiation dose for DLA-identical canine marrow grafts? Blood (1988) 0.87
The use of an anti-TCRalphabeta monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation (1999) 0.87
'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol (1994) 0.87
Study of the effect of pH, salinity and DOC on fluorescence of synthetic mixtures of freshwater and marine salts. J Environ Monit (1999) 0.86
Diagnosis of fetal arrhythmias using echocardiographic and Doppler techniques. J Am Coll Cardiol (1986) 0.86
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells (1996) 0.86
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant (2012) 0.86
Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol (2012) 0.84
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia (2005) 0.84
Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin. Bone Marrow Transplant (2012) 0.82
Current and future preparative regimens for bone marrow transplantation in thalassemia. Ann N Y Acad Sci (1998) 0.82
Late failure of autologous marrow grafts in lethally irradiated dogs given anti-class II monoclonal antibody. Blood (1991) 0.81
Stimulation of canine hematopoiesis by recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol (1989) 0.81
Ex vivo antimicrobial efficacy of the EndoVac system plus photodynamic therapy associated with calcium hydroxide against intracanal Enterococcus faecalis. Int Endod J (2012) 0.81
Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model. Blood (1998) 0.80
Prevention of graft-versus-host disease. Studies in a canine model. Ann N Y Acad Sci (1995) 0.80
Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann N Y Acad Sci (1999) 0.79
An antibody to CD44 enhances hematopoiesis in long-term marrow cultures. Exp Hematol (1996) 0.79
Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century. Transplant Proc (2000) 0.79
Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. Blood (2001) 0.79
Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment. Bone Marrow Transplant (2010) 0.78
Recognition of keratinocytes by cytotoxic T cells specific for conventional HLA class-I alloantigen. J Invest Dermatol (1990) 0.78
Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release. Immunol Invest (1995) 0.78
Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. Front Biosci (2001) 0.77
The expression and differentiation pattern of cell antigens and adhesion molecules on the nonadherent cell population in canine long-term marrow culture: a biphasic development of myeloid and lymphoid cells. Tissue Antigens (1998) 0.77
The influence of transfusions from unrelated DLA-matched or mismatched donors upon marrow grafts between DLA-identical canine littermates. Transplantation (1988) 0.76
Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor alpha. Cell Immunol (1995) 0.76
Non-myeloablative hematopoietic stem cell transplantation. Transfus Clin Biol (2001) 0.76
Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination. J Gen Virol (2002) 0.76
T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy (2002) 0.75
Successful management of concomitant Diamond-Blackfan anaemia and aplastic anaemia with splenectomy. Br J Haematol (1999) 0.75
Failure of interleukin-1 and granulocyte-macrophage colony-stimulating factor to enhance allogeneic marrow engraftment and survival in irradiated dogs. Blood (1995) 0.75
Vaccination of mice against Leishmania mexicana amazonensis with microsomal fraction associated with BCG. Ann Inst Pasteur Immunol (1988) 0.75
An organotypic skin culture model in dogs. A model for transplantation immunopathology in canine systems. Transplantation (1994) 0.75
Hodgkin's disease: the remaining challenge. Prog Med Virol (1984) 0.75
Lysis of keratinocytes by IL-2-activated peripheral blood lymphocytes. J Invest Dermatol (1991) 0.75
Antibody engagement of intercellular adhesion molecule 3 triggers apoptosis of normal and leukaemic myeloid marrow cells. Br J Haematol (2000) 0.75
CD8+ activated T lymphocytes produce an in vitro skin graft-versus-host reaction in an organotypic skin culture model. Transplantation (1995) 0.75
An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation. Transpl Immunol (1996) 0.75